LanteRNA
Pioneering advancements in nucleic acid technology for next-gen pharmaceuticals and medication delivery solutions.
Pioneering advancements in nucleic acid technology for next-gen pharmaceuticals and medication delivery solutions.
LanteRNA is a biotech startup founded in 2021 that is dedicated to pioneering advancements in nucleic acid technology for next-gen pharmaceuticals and medication delivery solutions. With a focus on developing nucleic acid labels, utilizing nucleic acid microscopy or spectroscopy, and understanding medication transport mechanisms, the company has emerged from the industrial research center for Functional RNA Delivery. Their specialization lies in the creation of next-generation nucleotide pharmaceuticals and advanced medication delivery systems.
Notably, Chalmers Ventures has shown faith in LanteRNA by participating in their kr300.00KPre Seed Round investment on 29 June 2022. The startup operates in the biotechnology, pharmaceutical, and marketing industries, demonstrating a broad scope and potential for impact within the healthcare and life sciences sectors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Pre Seed Round | kr300.00K | 1 |
|
29 Jun 2022 |
| Pre Seed Round | kr50.00K | - | 19 Oct 2021 |
No recent news or press coverage available for LanteRNA.
We care about your data, and we'd love to use cookies make your experience better.
